Latest database descriptions

Primary Objective: To describe the current therapeutic regimen for moderate and severe HA patients (ITI / on-demand / short-term prophylaxis / long-term prophylaxis) in the MS population.
Secondary Objectives:
- To describe the current therapeutic regimen (ITI / on-demand / short-term prophylaxis / long-term prophylaxis) in severe HA patients in the Sev population.
In both Moderate or Severe (MS) population and Severe (Sev) population :
- To describe the profile of patients with HA
- To describe the current treatment type according to therapeutic regimen, inhibitors status and severity
- To describe patient status regarding medical conditions and disease characteristics (severity, presence of inhibitors)
- To describe the patient’s musculoskeletal complications
In Severe (Sev) population:
- To describe medical history and related conditions
- To describe thrombosis events
- To describe therapeutic management administered to patients with severe HA from January 1, 2000 to the last visit (therapeutic regimens in the 2 years preceding the index date , therapeutic regimen from January 1, 2000 until 2 years preceeding the last visit)
- To describe ITI prescribed treatment from initial diagnosis
- To describe significant events (bleeding) or prevention of physical activities and their management occurring in the 2 years preceeding the last visit.
- To describe all surgeries occurring in the 2 years preceeding the last visit.
Exploratory Objectives:
- To identify factors associated with choice of therapeutic regimen (on-demand vs prophylaxis) in the Sev population with inhibitors status at last visit: “Never inhibitor” or “Tolerized inhibitor”.
- To identify factors associated with choice of therapeutic regimen (Prophylaxis vs on-demand, ITI vs on-demand) in the Sev population with inhibitors status at last visit: “Current inhibitor” .
- To identify factors associated with choice of ITI regimen (no ITI vs ITI) in the Sev population among patients with inhibitors.

Primary Objective: evaluate the efficacy and safety of bevacizumab as first-line treatment in participants with colorectal cancer and potentially resectable liver metastases.
Secondary Objectives:
- To describe patients’ characteristics treated with Avastin®,
- To describe the subgroup of patients with unresected missing metastases, with or without surgery,
- To describe criteria used to define unresectability,
- To describe progression-free survival in all patients,
- To describe relapse-free survival in all resected patients with no DMD,
- To describe overall survival in all patients,
- To describe histopathological response in resected patients,
- To describe Avastin® treatment modalities,
- To describe safety profile of Avastin®.

Primary Objective: To assess in real life the Progression-Free Survival at a maximum of 36 months follow-up, in patients suffering from metastatic colorectal cancer and initiating a treatment with Avastin® combined with chemotherapy.
Secondary Objectives:
- To describe characteristics of patients treated with Avastin®
- To describe the use of Avastin® over the study period
- To assess the overall survival of patients treated with Avastin®
- To describe the Avastin® safety profile (serious adverse events and/or unexpected related to Avastin®, and/or adverse events of special interest)
- To describe the quality of life of patients treated with Avastin®.
Exploratory Objective:
A search for the prognostic factors of PFS and OS was performed using a Cox model in patients treated with 1st line of chemotherapy (overall and in the subgroup of patients with synchronous metastases). These factors were determined from the characteristics of patients at inclusion.

Primary Objective: Progression-free survival in patients aged >= 75 years with metastatic colorectal cancer initiating first line treatment with Avastin®
Secondary Objectives:
- To describe the demographic, clinical and nutritional profiles of the patients and their living conditions and degree of autonomy;
- To describe the change in autonomy criteria;
- To describe the OS;
- To describe Avastin® dosage and regimen;
- To describe the safety profile of Avastin®.